If you have been reading about circadian clock and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-11-07. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small molecule | Studied as a REV-ERB agonist |
| Molecular formula | C20H24ClN3O4S | Reported for the neutral compound |
| Appearance | Off-white to pale yellow solid | Typical research-grade material |
| Solubility | Sparingly soluble in water | Soluble in solvents such as DMSO |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal alias |
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
=== Library === Bromley has a central library in the same building as the Churchill Theatre with a large book stock, Internet and wifi access, reference library and local studies department. It functions as the central library of the broader Bromley Borough Libraries Service, but is scheduled to be moved to another location on Bromley High Street as part of a major redevelopment. The new location is planned to open in 2026 with dedicated study and meeting areas and expanded children’s spaces. Other smaller libraries include the Burnt Ash Library, near the Sundridge Park area of Bromley, which was refurbished and reopened in February 2025 with improved lighting, accessible toilets, a better children’s area, and a new heating system as part of the borough’s wider library upgrade programme.
== Accumulation of toxic substances == In some areas of the United States where aquatic environments have tested positive for elevated levels of toxins, such as mercury, arsenic, chromium, and copper, signs are posted with warnings about the consumption of fish caught in those areas. Concentration of mercury biomagnifies as it passes up the food chain from organisms on lower trophic levels to apex predators. It bioaccumulates in the tissues of larger, long-lived, predatory fish. When compared to smaller, short-lived fish, bowfin tend to concentrate mercury at higher levels, thereby making them less safe for human consumption.
== Political effects == The Napoleonic Wars brought radical changes to Europe, but the reactionary forces returned and restored the Bourbon house to the French throne. Napoleon had succeeded in bringing most of Western Europe under one rule. In most European countries, subjugation in the French Empire brought with it many liberal features of the French Revolution including democracy, due process in courts, abolition of serfdom, reduction of the power of the Catholic Church, and demand for constitutional limits on monarchs. The increasing voice of the middle classes with rising commerce and industry meant that restored European monarchs found it difficult to restore pre-revolutionary absolutism and had to retain many of the reforms enacted during Napoleon's rule. Institutional legacies remain to this day in the form of civil law, with clearly defined codes of law—an enduring legacy of the Napoleonic Code.
Sources: en.wikipedia.org
The "grafting from" technique involves the generation of radicals along the polymer backbone from an abstraction of a halogen, from either the backbone or a functional group along the backbone. Monomers are reacted with the radicals along the backbone and subsequently generate polymers which are grafted from the backbone of the first polymer. The schematic for "grafting to" shows an example using anionic polymerizations, the polymer containing the carbonyl functionalities gets attacked by the activated polymer chain and generates a polymer attached to the associated carbon along with an alcohol group, in this example. These examples show us the potential of fine tuning end groups of polymer chains to target certain copolymer structures.
In A&P's traditional grocery stores, "wages and overhead expenses" had consumed 18 percent of sales, while in A&P's newly opened supermarkets in those same neighborhoods, those same numbers were less than 12 percent of sales. Once the large chains joined the supermarket trend, the new retail format exploded across the country like a wildfire. The number of American supermarkets almost tripled from 1,200 in 32 states in 1936 to over 3,000 in 47 states in 1937. It was well over 15,000 by 1950. One sign of the supermarket format's success in slashing labor costs, overhead, and food prices was that the percentage of disposable income spent by American consumers on food plunged "from 21 percent in 1930 to 16 percent in 1940". The modern era of "cheap food" had begun. As large chain stores began to dominate the American grocery landscape with their low overhead and low prices (while crushing numerous independent small stores along the way), a backlash to this radical alteration of food distribution infrastructure appeared in the form of numerous anti-chain campaigns. The idea of "monopsony", proposed by Cambridge economist Joan Robinson in 1933, that a single buyer could outmaneuver a market of multiple sellers, became a strong anti-chain rhetorical device. With public backlash came political pressure to even the playing field for smaller vendors lacking the luxury of economies of scale.
=== March === March 30, 2011: Wales The global credit information group Experian highlighted in a report that the economic recovery for Wales is slower than the rest of the UK, stating a forecasted growth of 1.6% per year over the next decade as compared to 2.2% for the rest of the United Kingdom. Issues for Wales were attributed to low export rates, an unskilled workforce and low entrepreneurism, leading to less opportunities for growth.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.
No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.
Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.